Shares of Karyopharm Therapeutics fell after the company launched a cash-retention program for executives.
The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date.
Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission.
Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000.
"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees," the company said in its filing.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
July 17, 2026 18:14 ET (22:14 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.